Portal de Periódicos da CAPES

A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease

2011; IOS Press; Volume: 22; Issue: 4 Linguagem: Inglês

10.3233/jad-2010-100939

1875-8908

Sofia Tzimopoulou, Vincent J. Cunningham, Thomas E. Nichols, Graham Searle, Nick Bird, Prafull Mistry, Ian Dixon, William Hallett, Brandon Whitcher, Andy Brown, Marina Zvartau‐Hind, Narinder Lotay, Robert Lai, Mary Castiglia, Barbara Jeter, Julian C. Matthews, Kewei Chen, Dan Bandy, Eric M. Reiman, Michael Gold, Eugenii A. Rabiner, Paul M. Matthews,

Metabolism and Genetic Disorders

Here we report the first multi-center clinical trial in Alzheimer's disease (AD) using fluorodeoxyglucose positron emission tomography ([18 F]FDG-PET) measures of brain glucose metabolism as the primary outcome. We contrasted effects of 12 months tre